Clene Nanomedicine
CLNN · Nasdaq · United States
Share price · CLNN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CLNN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-12.0%
Nothing announced by CLNN that day or the session before.
- 15 Sep 2026+22.6%
Nothing announced by CLNN that day or the session before.
- 14 Sep 2026-8.1%
Nothing announced by CLNN that day or the session before.
- 12 Aug 2026-6.9%
Nothing announced by CLNN that day or the session before.
- 11 Aug 2026-15.3%
- 5 May 2026-18.7%
- 4 May 2026+31.8%
- 6 Apr 2026+12.5%
Nothing announced by CLNN that day or the session before.
- 19 Mar 2026-10.7%
Nothing announced by CLNN that day or the session before.
- 29 Jan 2026-15.1%
Nothing announced by CLNN that day or the session before.
Share of unusual movement by asset
For each asset, the share of CLNN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
CNM-Au8events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 34% |
| Sessions with no dated event | — | 66% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | mitochondrial energy metabolismOther | Parkinson's DiseaseMultiple SclerosisAmyotrophic Lateral Sclerosis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.1M | $4.5M | $9.9M+ <$0.1M short-term inv. | —-$4.6M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.1M | $3.5M | $9.7M+ <$0.1M short-term inv. | $13M-$2.6M operating cash flow | report ↗ |
| 2026-Q1 | <$0.1M | $0.3M | $6.0M | $8.1M-$4.5M operating cash flow | report ↗ |
| 2025-Q3 | <$0.1M | $3.5M | $8.0M | $8.8M-$4.0M operating cash flow | report ↗ |
| 2025-Q2 | <$0.1M | $3.5M | $7.3M+ <$0.1M short-term inv. | $7.4M-$4.7M operating cash flow | report ↗ |
| 2025-Q1 | $0.1M | $1.5M | $9.9M | $0.8M-$5.0M operating cash flow | report ↗ |
| 2024-Q3 | $0.1M | $4.5M | $15M+ $0 short-term inv. | $8.0M-$3.0M operating cash flow | report ↗ |
| 2024-Q2 | $0.1M | $4.2M | $22M+ $0 short-term inv. | $6.8M-$6.4M operating cash flow | report ↗ |
| 2024-Q1 | $0.1M | $5.9M | $22M+ $6.2M short-term inv. | $11M-$7.1M operating cash flow | report ↗ |
| 2023-Q3 | $0.1M | $6.0M | $42M+ $0 short-term inv. | $2.4M-$6.8M operating cash flow | report ↗ |
| 2023-Q2 | $0.3M | $6.6M | $49M+ $0 short-term inv. | $25M-$7.0M operating cash flow | report ↗ |
| 2023-Q1 | $0.1M | $7.4M | $19M+ $0 short-term inv. | $12M-$9.2M operating cash flow | report ↗ |
| 2022-Q3 | $0.2M | $6.4M | $7.3M+ $9.0M short-term inv. | $11M-$8.5M operating cash flow | report ↗ |
| 2022-Q2 | <$0.1M | $9.2M | $7.3M+ $19M short-term inv. | $4.5M-$9.7M operating cash flow | report ↗ |
| 2022-Q1 | <$0.1M | $8.6M | $13M+ $24M short-term inv. | $13M-$13M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $6.2M | $61M | —-$7.3M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.2M | $14M | $5.3M+ <$0.1M short-term inv. | $6.5M-$19M operating cash flow | report ↗ |
For fiscal year 2025, Clene reported revenue of $0.2M, down 41.2% YoY, with R&D spend of $14.01M, down 30.2% YoY. Cash and equivalents stood at $5.25M, and the company reported a net loss of $26.17M, with a disclosed quarterly net burn of $26.17M.
The 10-K describes ongoing CNM-Au8 clinical programs in amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease, along with regulatory activities for CNM-Au8 and CNM-ZnAg nonclinical work. The filing also discloses material weaknesses in internal control over financial reporting and notes a subsequent January 2026 public equity offering.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.3M | $20M | $12M+ $0 short-term inv. | $9.8M-$21M operating cash flow | report ↗ |
| 2023-FY | $0.7M | $27M | $29M+ $6.2M short-term inv. | $12M-$30M operating cash flow | report ↗ |
| 2022-FY | $0.5M | $32M | $18M+ $5.0M short-term inv. | $7.5M-$39M operating cash flow | report ↗ |
| 2021-FY | $0.7M | $28M | $50M+ $0 short-term inv. | $2.4M-$35M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($251K), 62 sales ($5.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | WILCOX REED N · director | Open-market purchase | 8,000 | $3.42 | $27K | Form 4 |
| 2026-11-18 | WILCOX REED N · director | Open-market purchase | 2,000 | $3.44 | $7K | Form 4 |
| 2026-11-12 | WILCOX REED N · director | Award / grant (derivative) | 3,395 | — | — | Form 4 |
| 2026-11-12 | McLaughlin Vallerie · director | Award / grant (derivative) | 3,395 | — | — | Form 4 |
| 2026-11-12 | Gay Jonathon · director | Award / grant (derivative) | 3,665 | — | — | Form 4 |
| 2026-11-12 | MATLIN DAVID J · director | Award / grant (derivative) | 6,019 | — | — | Form 4 |
| 2026-11-12 | Kiernan Matthew · director | Award / grant (derivative) | 3,086 | — | — | Form 4 |
| 2026-11-12 | Mosca Alison · director, 10% owner | Award / grant (derivative) | 4,707 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 29 reporting institutions held 2.2M shares ($10.8M, 15.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Boxer Capital Management, LLC | 477,515 | $2.4M |
| 2 | SymBiosis Capital Partners, LLC | 431,094 | $2.1M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 308,230 | $1.5M |
| 4 | SCOGGIN MANAGEMENT LP | 300,000 | $1.5M |
| 5 | Ensign Peak Advisors, Inc | 257,872 | $1.3M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 95,874 | $473K |
| 7 | Lunt Capital Management, Inc. | 52,260 | $258K |
| 8 | PEAK6 LLC | 50,012 | $247K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 43,715 | $216K |
| 10 | PARSONS CAPITAL MANAGEMENT INC/RI | 37,243 | $184K |
| 11 | BlackRock, Inc. | 33,799 | $167K |
| 12 | STATE STREET CORP | 29,801 | $147K |
| 13 | MORGAN STANLEY | 19,832 | $98K |
| 14 | NORTHERN TRUST CORP | 16,143 | $80K |
| 15 | PENN DAVIS MCFARLAND INC | 11,000 | $54K |